20.05.2025 13:04:44
|
Quoin Pharma Gets Orphan Drug Status In Europe For QRX003 In Netherton Syndrome
(RTTNews) - Quoin Pharmaceuticals Ltd. (QNRX) Tuesday said that it has received Orphan Drug Designation in Europe by the European Medicines Agency (EMA) for its lead drug candidate QRX003 in Netherton Syndrome. Orphan Drug Designation in Europe offers various benefits including reduced fees, market exclusivity, and access to scientific advice.
QRX003 is currently being evaluated in multiple late-stage studies in Netherton Syndrome.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Quoin Pharmaceuticals, Ltd (spons. ADRs)mehr Nachrichten
Keine Nachrichten verfügbar. |